Knuiman G, Kusters B, Eshuis L, Snoeck M, Lammens M, Heytens L
J Neurol. 2019; 266(4):876-887.
PMID: 30788618
PMC: 6420893.
DOI: 10.1007/s00415-019-09209-z.
Klingler W, Heiderich S, Girard T, Gravino E, Heffron J, Johannsen S
Orphanet J Rare Dis. 2014; 9:8.
PMID: 24433488
PMC: 3896768.
DOI: 10.1186/1750-1172-9-8.
Jungbluth H
Orphanet J Rare Dis. 2007; 2:25.
PMID: 17504518
PMC: 1887524.
DOI: 10.1186/1750-1172-2-25.
Graves T, Hanna M
Postgrad Med J. 2005; 81(951):20-32.
PMID: 15640425
PMC: 1743173.
DOI: 10.1136/pgmj.2004.022012.
Barone V, Massa O, Intravaia E, Bracco A, Di Martino A, Tegazzin V
J Med Genet. 1999; 36(2):115-8.
PMID: 10051009
PMC: 1734304.
Intracellular calcium homeostasis in human primary muscle cells from malignant hyperthermia-susceptible and normal individuals. Effect Of overexpression of recombinant wild-type and Arg163Cys mutated ryanodine receptors.
Censier K, Urwyler A, Zorzato F, Treves S
J Clin Invest. 1998; 101(6):1233-42.
PMID: 9502764
PMC: 508677.
DOI: 10.1172/JCI993.
Identification of novel mutations in the ryanodine-receptor gene (RYR1) in malignant hyperthermia: genotype-phenotype correlation.
Manning B, Quane K, Ording H, Urwyler A, Tegazzin V, Lehane M
Am J Hum Genet. 1998; 62(3):599-609.
PMID: 9497245
PMC: 1376943.
DOI: 10.1086/301748.
A novel process for mutation detection using uracil DNA-glycosylase.
Vaughan P, McCarthy T
Nucleic Acids Res. 1998; 26(3):810-5.
PMID: 9443974
PMC: 147313.
DOI: 10.1093/nar/26.3.810.
Malignant-hyperthermia susceptibility is associated with a mutation of the alpha 1-subunit of the human dihydropyridine-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle.
Monnier N, Procaccio V, STIEGLITZ P, Lunardi J
Am J Hum Genet. 1997; 60(6):1316-25.
PMID: 9199552
PMC: 1716149.
DOI: 10.1086/515454.
Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes.
Keating K, Giblin L, Lynch P, Quane K, Lehane M, Heffron J
J Med Genet. 1997; 34(4):291-6.
PMID: 9138151
PMC: 1050914.
DOI: 10.1136/jmg.34.4.291.
The G1021A substitution in the RYR1 gene does not cosegregate with malignant hyperthermia susceptibility in a British pedigree.
Adeokun A, West S, Ellis F, Halsall P, Hopkins P, Foroughmand A
Am J Hum Genet. 1997; 60(4):833-41.
PMID: 9106529
PMC: 1712455.
Rapid, simple and sensitive microassay for skeletal muscle homogenates in the functional assessment of the Ca-release channel of sarcoplasmic reticulum: application to diagnosis of susceptibility to malignant hyperthermia.
OBrien P, Li G
Mol Cell Biochem. 1997; 167(1-2):61-72.
PMID: 9059982
DOI: 10.1023/a:1006867521140.
[Molecular pathogenesis of muscular diseases].
Ohlendieck K
Naturwissenschaften. 1996; 83(12):555-65.
PMID: 9036337
Diagnosis of malignant hyperthermia: a comparison of the in vitro contracture test with the molecular genetic diagnosis in a large pedigree.
Healy J, Quane K, Keating K, Lehane M, Heffron J, McCarthy T
J Med Genet. 1996; 33(1):18-24.
PMID: 8825043
PMC: 1051806.
DOI: 10.1136/jmg.33.1.18.
Exclusion of defects in the skeletal muscle specific regions of the DHPR alpha 1 subunit as frequent causes of malignant hyperthermia.
OBrien R, Taske N, Hansbro P, Matthaei K, Hogan S, Denborough M
J Med Genet. 1995; 32(11):913-4.
PMID: 8592342
PMC: 1051750.
DOI: 10.1136/jmg.32.11.913.
Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1.
Sudbrak R, Procaccio V, Klausnitzer M, Curran J, Monsieurs K, Van Broeckhoven C
Am J Hum Genet. 1995; 56(3):684-91.
PMID: 7887423
PMC: 1801161.
Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 caucasian families.
Elbaz A, Jurkat-Rott K, Lapie P, Ophoff R, BADY B, Links T
Am J Hum Genet. 1995; 56(2):374-80.
PMID: 7847370
PMC: 1801148.